Coherus Biosciences (CHRS)

Company Profile

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system.

Company profile

Ticker

CHRS

Exchange

NASDAQ

Website

www.coherus.com

CEO

Dennis Lanfear

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...

Former names

BioGenerics, Inc.

SEC CIK

0001512762

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

CHRS stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$16.00

Low target

$11.00

High target

$21.00

Latest filings (excl ownership)

View all

S-8

Registration of securities for employees

Notice of effectiveness

18 Nov 22

424B5

Prospectus supplement for primary offering

17 Nov 22

CORRESP

Correspondence with SEC

8 Nov 22

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

8 Nov 22

8-K/A

Submission of Matters to a Vote of Security Holders

6 Oct 22

Transcripts

View all

CHRS

Earnings call transcript

2022 Q2

7 Aug 22

CHRS

Earnings call transcript

2022 Q1

6 May 22

CHRS

Earnings call transcript

2021 Q4

18 Feb 22

CHRS

Earnings call transcript

2021 Q3

9 Nov 21

CHRS

Earnings call transcript

2021 Q2

8 Aug 21

CHRS

Earnings call transcript

2021 Q1

10 May 21

CHRS

Earnings call transcript

2020 Q4

25 Feb 21

CHRS

Earnings call transcript

2020 Q3

8 Nov 20

CHRS

Earnings call transcript

2020 Q2

8 Aug 20

CHRS

Earnings call transcript

2020 Q1

9 May 20

Latest ownership filings

View all

Financial summary

Financial statements Chart CHRS financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	287.25 mm	287.25 mm	287.25 mm	287.25 mm	287.25 mm	287.25 mm
Cash burn (monthly)	(no burn)	6.14 mm	28.88 mm	23.22 mm	12.36 mm	16.12 mm
Cash used (since last report)	n/a	24.34 mm	114.40 mm	91.96 mm	48.97 mm	63.87 mm
Cash remaining	n/a	262.91 mm	172.84 mm	195.28 mm	238.28 mm	223.38 mm
Runway (months of cash)	n/a	42.8	6.0	8.4	19.3	13.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

CHRS institutional ownership history Ownership history

98.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	170	175	-2.9%
Opened positions	20	24	-16.7%
Closed positions	25	32	-21.9%
Increased positions	69	73	-5.5%
Reduced positions	56	53	+5.7%

13F shares	Current	Prev Q	Change
Total value	810.83 mm	688.40 mm	+17.8%
Total shares	76.19 mm	82.85 mm	-8.0%
Total puts	15.00 k	27.00 k	-44.4%
Total calls	0.00	437.00 k	EXIT
Total put/call ratio	Infinity	0.1	+Infinity%

Largest owners	Shares	Value	Change
BLK Blackrock	12.98 mm	$124.79 mm	+0.8%
Temasek	7.38 mm	$70.93 mm	0.0%
JPM JPMorgan Chase & Co.	6.13 mm	$58.86 mm	-5.6%
Alliancebernstein	6.11 mm	$58.69 mm	+7.6%
Vanguard	5.23 mm	$50.25 mm	+7.1%
KKR Group Partnership	3.95 mm	$116.48 mm	0.0%
Kohlberg Kravis Roberts & Co.	3.04 mm	$29.18 mm	0.0%
Aristotle Capital Boston	2.14 mm	$20.58 mm	-7.8%
AMP Ameriprise Financial	1.83 mm	$17.55 mm	-6.1%
Perceptive Advisors	1.67 mm	$16.02 mm	-54.3%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-6.38 mm	EXIT
Perceptive Advisors	1.67 mm	-1.98 mm	-54.3%
Disciplined Growth Investors	1.13 mm	+886.08 k	+360.2%
Alliancebernstein	6.11 mm	+431.41 k	+7.6%
Nordea Investment Management Ab	0.00	-388.05 k	EXIT
JPM JPMorgan Chase & Co.	6.13 mm	-360.99 k	-5.6%
Two Sigma Investments	369.78 k	+351.21 k	+1890.4%
Vanguard	5.23 mm	+345.29 k	+7.1%
Jacobs Levy Equity Management	571.85 k	-316.74 k	-35.6%
Phocas Financial	0.00	-316.46 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CHRS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jan 23	McDavid Stilwell	Common Stock	Grant	Acquire A	No	No	0	40,000	0.00	104,243
20 Jan 23	Vladimir Vexler	Common Stock	Grant	Acquire A	No	No	0	40,000	0.00	131,323
20 Jan 23	Bryan J McMichael	Common Stock	Grant	Acquire A	No	No	0	12,500	0.00	26,386
20 Jan 23	Dennis M Lanfear	Common Stock	Grant	Acquire A	No	No	0	86,250	0.00	654,853
11 Jan 23	Vladimir Vexler	Common Stock	Payment of exercise	Dispose F	No	No	10.26	3,602	36.96 k	91,323
10 Jan 23	Vladimir Vexler	Common Stock	Payment of exercise	Dispose F	No	No	9.85	3,602	35.48 k	94,925